1. Home
  2. RCKT vs BACQ Comparison

RCKT vs BACQ Comparison

Compare RCKT & BACQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCKT
  • BACQ
  • Stock Information
  • Founded
  • RCKT 1999
  • BACQ 2024
  • Country
  • RCKT United States
  • BACQ United States
  • Employees
  • RCKT N/A
  • BACQ N/A
  • Industry
  • RCKT Biotechnology: Pharmaceutical Preparations
  • BACQ
  • Sector
  • RCKT Health Care
  • BACQ
  • Exchange
  • RCKT Nasdaq
  • BACQ NYSE
  • Market Cap
  • RCKT 326.4M
  • BACQ 347.7M
  • IPO Year
  • RCKT N/A
  • BACQ 2024
  • Fundamental
  • Price
  • RCKT $2.70
  • BACQ $10.37
  • Analyst Decision
  • RCKT Buy
  • BACQ
  • Analyst Count
  • RCKT 13
  • BACQ 0
  • Target Price
  • RCKT $18.50
  • BACQ N/A
  • AVG Volume (30 Days)
  • RCKT 8.4M
  • BACQ 92.3K
  • Earning Date
  • RCKT 08-04-2025
  • BACQ 01-01-0001
  • Dividend Yield
  • RCKT N/A
  • BACQ N/A
  • EPS Growth
  • RCKT N/A
  • BACQ N/A
  • EPS
  • RCKT N/A
  • BACQ N/A
  • Revenue
  • RCKT N/A
  • BACQ N/A
  • Revenue This Year
  • RCKT N/A
  • BACQ N/A
  • Revenue Next Year
  • RCKT N/A
  • BACQ N/A
  • P/E Ratio
  • RCKT N/A
  • BACQ $115.18
  • Revenue Growth
  • RCKT N/A
  • BACQ N/A
  • 52 Week Low
  • RCKT $2.19
  • BACQ $9.80
  • 52 Week High
  • RCKT $26.98
  • BACQ $10.45
  • Technical
  • Relative Strength Index (RSI)
  • RCKT 32.09
  • BACQ N/A
  • Support Level
  • RCKT $2.66
  • BACQ N/A
  • Resistance Level
  • RCKT $3.33
  • BACQ N/A
  • Average True Range (ATR)
  • RCKT 0.28
  • BACQ 0.00
  • MACD
  • RCKT 0.09
  • BACQ 0.00
  • Stochastic Oscillator
  • RCKT 26.59
  • BACQ 0.00

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

About BACQ BLEICHROEDER ACQUISITION CORP. I

Bleichroeder Acquisition Corp I is a blank check company.

Share on Social Networks: